First patient has been enrolled in the 17,000 patient AEGIS-II trial investigating whether infusing CSL112 (human apo-AI) reduces cardiovascular events (3-point MACE) in high-risk patients during the critical 90 days after a heart attack. Could be a great test of the HDL hypothesis. Trial won't complete until 2021 or 2022, so we'll have our answer on apabetalone by then. Perhaps optimal therapy is CSL112 infusion right after ACS, then continue on apabetalone?

https://clinicaltrials.gov/ct2/show/NCT03473223

https://twitter.com/CMichaelGibson/status/976559990814203904